A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 901–1,000 of 1,003
Cancer biotherapy: review and prospect
Liu, Q., & Ma, H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01376-2 · Cited by 11
Moharramnejad, M., Sayah, T., Ghehsareh, Z., Rezaei, M. M., Karimi, F., Amini, A. H., Malekshah, R. E., Shahi, M., Mirtamizdoust, B., Ehsani, A., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106320 · Cited by 11
Hsu, C., Chandramoorthy, H. C. K., Mohammed, J. S., Al-Hasnaawei, S., Yaqob, M., Kundlas, M., Samikan, K., Sahoo, S., Sunori, S. K., & Abbas, Z. A. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04237-4 · Cited by 11
Bayesian multiple instance regression for modeling immunogenic neoantigens
Park, S., Wang, X., Lim, J., Xiao, G., Lu, T., & Wang, T. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220914321 · Cited by 11
Solomon, B., Beavis, P. A., & Darcy, P. K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281101 · Cited by 11
Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion
Lopatina, T., Sarcinella, A., & Brizzi, M. F. (2022) · Cancers · doi:10.3390/cancers14164020 · Cited by 11
Neoantigen Discovery in Human Cancers
Mardis, E. R. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000248 · Cited by 11
Self-citationVaccines for Non-Viral Cancer Prevention
Bayó, C., Jung, G., Español‐Rego, M., Balaguer, F., & Benítez‐Ribas, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010900 · Cited by 11
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
Wang, C., Shi, Y., Zhang, D., Sun, Y., Xie, J., Wu, B., Zhang, C., & Liu, X. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00225-3 · Cited by 10
Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review)
Feng, H., Jin, Y., & Wu, B. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5749 · Cited by 10
Kim, M. E., & Lee, J. S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100806 · Cited by 10
Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors
Hoover, A. R., Kaabinejadian, S., Krawic, J. R., Sun, X.-H., Naqash, A. R., Yin, Q., Yang, X., García, K. C., Davis, M. M., Hildebrand, W. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004973 · Cited by 10
Self-citationPersonalized Neoantigen DNA Cancer Vaccines: Current Status and Future Perspectives
Viborg, N., Kleine‐Kohlbrecher, D., & Rønø, B. (2024) · Journal of Cellular Immunology · doi:10.33696/immunology.6.188 · Cited by 10
Proteomimetic Polymers Trigger Potent Antigen-Specific T Cell Responses to Limit Tumor Growth
Wang, M. M., Choi, M.-R., Battistella, C., Gattis, B. S., Qiao, B., Evangelopoulos, M., Mirkin, C. A., de la Cruz, M. O., Zhang, B., & Gianneschi, N. C. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05340 · Cited by 10
Bibliometric analysis of dendritic cell-based vaccines over the past 15 years
Zhi Gao, L. O. N. G., Wu, Y., Zhong, L., Lu, J., & Liu, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2392961 · Cited by 10
A recent perspective on designing tumor vaccines for tumor immunology
Cao, S., Jia, W., Zhao, Y., Liu, H., Cao, J., & Li, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113090 · Cited by 10
Hu, C., Nong, S., Ke, Q., Wu, Z., Jiang, Y., Wang, Y., Chen, Y., Wu, Z., Zhang, Q., Liao, C., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112274 · Cited by 10
Weakly supervised peptide-TCR binding prediction facilitates neoantigen identification
Gao, Y., Gao, Y., Wu, S., Li, D., Zhou, C., Meng, F., Dong, K., Zhao, X., Li, P., Liang, A., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101403 · Cited by 10
Ferrari, V., Tarke, A., Fields, H. F., Ferrari, L., Conley, T., Ferrari, F., Koşaloğlu‐Yalçın, Z., Sette, A., Peters, B., McCarthy, C., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.10.003 · Cited by 10
Joyce, S., & Ternette, N. (2021) · PROTEOMICS · doi:10.1002/pmic.202000143 · Cited by 10
Guiding immunotherapy combinations: Who gets what?
Ferreira, M., & Choe, J. H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113962 · Cited by 10
Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
Nettersheim, F. S., Picard, F. S. R., Hoyer, F. F., & Winkels, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812702 · Cited by 10
Shi, W., Chen, S., Chi, F., Qiu, Q., Zhong, Y., Bian, X., Zhang, H., Xi, J., & Qian, H. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200239 · Cited by 10
Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer
Miao, S., Ju, G., Jiang, C., Xue, B., Zhao, L., Zhang, R., Diao, H., Yu, X., Zhang, L., Pan, X., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1167676 · Cited by 10
Harnessing the immune system for the treatment of melanoma: current status and future prospects
Guennoun, A., Sidahmed, H., Maccalli, C., Seliger, B., Marincola, F. M., & Bedognetti, D. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1176529 · Cited by 10
Personalized peptide vaccines for cancer therapy: current progress and state of the art
Wada, S., Yada, E., Ohtake, J., & Sasada, T. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1403286 · Cited by 10
Tan, Q., Ku, W., Zhang, C., Palashati, H., Tian, Y., Ke, Y., & Lu, Z. (2017) · Immunology and Cell Biology · doi:10.1111/imcb.1030 · Cited by 10
Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation
Bai, P., Zhou, Q., Wei, P., Bai, H., Chan, S. K., Kappler, J. W., Marrack, P., & Yin, L. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1888-1 · Cited by 10
Investigation of parameters that determine Nano-DC vaccine transport
Zhang, J., Mai, J., Li, F., Shen, J., Zhang, G., Li, J., Hinkle, L. E., Lin, D., Liu, X., Li, Z., et al. (2019) · Biomedical Microdevices · doi:10.1007/s10544-019-0397-6 · Cited by 10
Moreira, A., Erdmann, M., Uslu, U., Vass, V., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030210 · Cited by 10
Oseni, S. O., Wang, Y., & Hwu, P. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.013 · Cited by 9
Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 9
Self-citationMorisaki, S., Onishi, H., Morisaki, T., Kubo, M., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Tsujimura, K., Yoshimura, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223331 · Cited by 9
SIGANEO: Similarity network with GAN enhancement for immunogenic neoepitope prediction
Ye, Y., Shen, Y., Wang, J., Li, D., Zhu, Y., Zhao, Z., Pan, Y., Wang, Y., Liu, X., & Wan, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.050 · Cited by 9
Challenges and Opportunities of Nanomedicine: Novel Comprehensive Approaches for Brain Metastasis
Xiang, Y., Li, Z., Pan, D., Gong, Q., Luo, K., & Liu, Y. (2023) · Small Structures · doi:10.1002/sstr.202300148 · Cited by 9
Yoshizaki, Y., Horii, K., Murase, N., Kuzuya, A., & Ohya, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123801 · Cited by 9
Tumor Antigens beyond the Human Exome
Emilius, L., Bremm, F., Binder, A. K., Schaft, N., & Dörrie, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094673 · Cited by 9
Gielis, S., Flumens, D., van der Heijden, S., Versteven, M., Reu, H. D., Bartholomeus, E., Schippers, J., Campillo-Davó, D., Berneman, Z. N., Anguille, S., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05919-1 · Cited by 9
Dendritic Cells: The Tools for Cancer Treatment
Locy, H., Melhaoui, S., Maenhout, S. K., & Thielemans, K. (2018) · InTech eBooks · doi:10.5772/intechopen.79273 · Cited by 9
Personalized Neo-Epitope Vaccines for Cancer Treatment
Vormehr, M., Diken, M., Türeci, Ö., Şahin, U., & Kreiter, S. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_5 · Cited by 9
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy
Jazirehi, A. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111726 · Cited by 9
Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity
Lu, Y., Liu, X., & You, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102129 · Cited by 9
Tailoring the Treatment of Melanoma: Implications for Personalized Medicine.
Duan, L., Mukherjee, E. M., & Narayan, D. (2015) · PubMed Central · Cited by 9
Omokoko, T., Luxemburger, U., Bardissi, S., Simon, P., Utsch, M., Breitkreuz, A., Türeci, Ö., & Şahin, U. (2016) · Journal of Immunology Research · doi:10.1155/2016/9540975 · Cited by 9
Aris, M., Bravo, A., Alvarez, H. M. G., Carri, I., Podaza, E., Blanco, P. A., Rotondaro, C., Bentivegna, S., Nielsen, M., Barrio, M. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02213 · Cited by 9
Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 9
Lao, Y., Wang, Y., Yang, J., Liu, T., Ma, Y., Luo, Y., Sun, Y., Li, K., Zhao, X., Niu, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941868 · Cited by 9
Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer
Yin, Q., Tang, J., & Zhu, X. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely018 · Cited by 9
Huang, J., Song, S., Yin, Y., He, Y., Wang, H., Gu, Y., He, L., Wang, X., Miao, X., Zhang, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1528532 · Cited by 8
Bacterial Foreignization Nanosystem Elicits Multi‐Phenotypic T Cells for Antitumor Immunity
Zhuang, W., Xue, W., Liang, C., Liu, P., Lei, Y., He, J., Cheng, R., Nie, W., Wang, J., Tang, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202504155 · Cited by 8
Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
Hannani, D., Leplus, E., Laulagnier, K., Chaperot, L., & Plumas, J. (2023) · Genes & Cancer · doi:10.18632/genesandcancer.229 · Cited by 8
Bayó, C., Castellano, G., Marín, F., Castillo‐Iturra, J., Ocaña, T., Kumari, H., Pellisé, M., Moreira, L., Rivero, L., Daca-Álvarez, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011177 · Cited by 8
Muñoz, L. E., Monterroza, L., Bommireddy, R., Shafizadeh, Y., Pack, C. D., Ramachandiran, S., Reddy, S. J. C., & Selvaraj, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168377 · Cited by 8
Position‐Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T‐Cell Responses
He, X., Zhou, S., Quinn, B., Huang, W., Jahagirdar, D., Vega, M., Ortega, J., Long, M. D., Ito, F., Abrams, S. I., et al. (2021) · Advanced Science · doi:10.1002/advs.202103023 · Cited by 8
Is There a Role for Immunotherapy in Central Nervous System Cancers?
Flores, C. T., Dunn, G. P., Fecci, P. E., Lim, M. K., Mitchell, D. A., & Reardon, D. A. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.09.002 · Cited by 8
Strategy and application of manipulating DCs chemotaxis in disease treatment and vaccine design
Lu, Y., & You, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114457 · Cited by 8
Dou, X., Peng, M., Jiang, R., Li, W., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174406 · Cited by 8
Moon, D. O. (2024) · Cancers · doi:10.3390/cancers16091674 · Cited by 8
New Immunotherapies in Oncology Treatment and Their Side Effect Profiles
Sriratana, P., & Norton, J. A. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.04.170387 · Cited by 8
Zhang, S., Chen, J., Hong, P., Li, J., Tian, Y., Wu, Y., & Wang, S. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.112685 · Cited by 8
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study
Punta, M., Jennings, V. A., Melcher, A. A., & Lise, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.524968 · Cited by 8
Ke, C., Wang, Y., Chiang, H.-C., Wu, H., Liu, W.-J., Huang, C.-C., Huang, Y.-C., & Lin, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.012 · Cited by 8
Liao, W., Huang, S., Lin, L., Wang, J., Li, J., Chen, Y., Chen, L., Lian, Y., & Huang, Y. (2022) · Cancers · doi:10.3390/cancers15010109 · Cited by 8
Gao, S., Wang, J., Zhu, Z., Fang, J., Zhao, Y., Liu, Z., Qin, H., Wei, Y., Xu, H., Dan, X., et al. (2023) · Immunotherapy · doi:10.2217/imt-2021-0339 · Cited by 8
Carter, J. A., Matta, B., Battaglia, J., Somerville, C. C., Harris, B. D., LaPan, M., Atwal, G. S., & Barnes, B. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007935 · Cited by 8
Necroptotic‐susceptible dendritic cells exhibit enhanced antitumor activities in mice
Zhao, Z., Zhang, G., Sun, Y., & Winoto, A. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.330 · Cited by 8
Outsourcing the immune response to cancer
Yadav, M., & Delamarre, L. (2016) · Science · doi:10.1126/science.aag1547 · Cited by 8
neoepiscope improves neoepitope prediction with multi-variant phasingPreprint
Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/418129 · Cited by 8
Zhou, W., Yu, J., Li, F., Huang, Y.-T., Du, J., Wu, A., & Wang, K. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01370-1 · Cited by 7
Khanmiri, J. M., Khani-Eshratabadi, M., Seyedmoharrami, F., Khazaee‐Nasirabadi, M. H., Dehdashti, M., Seddighi, N., Peymaninezhad, F., Khiabani, A., Khanahmad, A., & Baradaran, B. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02056-z · Cited by 7
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
Ashi, M. O., Mami‐Chouaib, F., & Corgnac, S. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00111 · Cited by 7
Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024
Jia, Z., Zhang, Y., Cao, L., Wang, J., & Liang, H. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2464379 · Cited by 7
Chasing neoantigens; invite naïve T cells to the party
Bollineni, R. C., Tran, T. T., Lund‐Johansen, F., & Olweus, J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102172 · Cited by 7
Vaccination and Microbiota Manipulation Approaches for Colon Cancer Prevention in Rodent Models
Tosti, E., Srivastava, N., & Edelmann, W. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0015 · Cited by 7
Antigenic targets in clear cell renal cell carcinoma
Schindler, N. R., & Braun, D. A. (2023) · Kidney Cancer · doi:10.3233/kca-230006 · Cited by 7
CanVaxKB: a web-based cancer vaccine knowledgebase
Asfaw, E. K., Lin, Y., Huffman, A., Li, S., George, M., Darancou, C., Kalter, M., Wehbi, N., Bartels, D., Fleck, E. M. A., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcad060 · Cited by 7
Kreidieh, F., & Wong, M. K. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128341628250519093548 · Cited by 7
Gallou, C., Rougeot, A., Graff‐Dubois, S., Kosmatopoulos, K., & Menez-Jamet, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11086 · Cited by 7
Yu, G., Moudgil, T. L., Cui, Z.-H., Mou, Y., Wang, L., Fox, B. A., & Hu, H. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000165 · Cited by 7
Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE
Yoshikawa, S., Kiyohara, Y., Otsuka, M., Kondou, R., Nonomura, C., Miyata, H., Iizuka, A., Ohshima, K., Urakami, K., Nagashima, T., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11450 · Cited by 7
Thakur, S. S., Ruan, Y., Zhang, C., Lun, X. Q., Jayanthan, A., & Narendran, A. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0199-2 · Cited by 7
The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model
Faktor, J., Grasso, G. I., Kokas, F. Z., Kurkowiak, M., Mayordomo, M. Y., Kote, S., Singh, A. J., Li, R., O’Neill, J. R., Müller, P., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129722 · Cited by 7
Getting personal about skin: Realizing precision medicine in dermatology
Brownstone, N. D., Wu, J. J., Strober, B. E., & Dickerson, T. J. (2021) · Dermatological Reviews · doi:10.1002/der2.99 · Cited by 7
What do cancer-specific T cells ‘see’?
Shah, S., Al‐Omari, A., Cook, K., Paston, S. J., Durrant, L. G., & Brentville, V. A. (2022) · Discovery Immunology · doi:10.1093/discim/kyac011 · Cited by 7
[Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
(2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.40 · Cited by 7
Personalized mRNA Vaccines and Contemporary Melanoma Practice
Hieken, T. J., & Ariyan, C. E. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15731-w · Cited by 7
Shafer, P. W., Leung, W. K., Woods, M. L., Choi, J. M., Rodriguez-Plata, C. M., Maknojia, A., Mosquera, A., Somes, L. K., Joubert, J., Manliguez, A., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2023.12.002 · Cited by 6
Research and Clinical Progress of Therapeutic Tumor Vaccines
Dong, C., Zhuang, L., Tan, D., Sun, H., Liang, J., Wei, D., Zheng, Y., Zhang, L., Liu, S., Zhang, Y., et al. (2025) · Vaccines · doi:10.3390/vaccines13070672 · Cited by 6
Deng, Z., Li, L., Yang, Z., Zeng, G., & Liu, R. (2025) · BMC Immunology · doi:10.1186/s12865-025-00733-4 · Cited by 6
Beg, M. M. A., Aslam, M., Ayaz, A., Akhtar, M. S., & Zaman, W. (2025) · Cells · doi:10.3390/cells14181453 · Cited by 6
Booming cancer immunotherapy fighting tumors
Li, D., & Wang, W. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9208-1 · Cited by 6
Towards customized cancer vaccines: a promising filed in personalized cancer medicine
Xu, X., Zhou, Z., Li, H., & Fan, Y. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1909479 · Cited by 6
Thakur, S. S., Jain, M., Zhang, C., Major, C., Bielamowicz, K., Lacayo, N. J., Vaske, O. M., Lewis, V. A., Murguía-Favela, L. E., & Narendran, A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2001243 · Cited by 6
A Brief Overview of Cancer Vaccines
Muller, A. J., Thomas, S., & Prendergast, G. C. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000640 · Cited by 6
A Winning New Combination? Toward Clinical Application in Oncology
Maqsood, Q., Sumrin, A., Iqbal, M., Hussain, N., Mahnoor, M., Saleem, M. Z., & Perveen, R. (2023) · Cancer Control · doi:10.1177/10732748231175240 · Cited by 6
Ningoo, M., Cruz‐Encarnacion, P., Khilnani, C. K., Heeger, P. S., & Fribourg, M. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.12.016 · Cited by 6
Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence
Zakariya, F., Salem, F. K., Alamrain, A. A., Sanker, V., Abdelazeem, Z. G., Hosameldin, M., Tan, J. K., Howard, R., Huang, H. Y. R., & Awuah, W. A. (2024) · European journal of medical research · doi:10.1186/s40001-023-01625-2 · Cited by 6
The Immunopeptidomics Ontology (ImPO)
Faria, D., Eugénio, P., Silva, M. C., Balbi, L., Bedran, G., Kallor, A. A., Nunes, S., Pałkowski, A., Waleron, M. M., Alfaro, J. A., et al. (2024) · Database · doi:10.1093/database/baae014 · Cited by 6
Long-range alternative splicing contributes to neoantigen specificity in glioblastoma
Ji, M., Yu, Q., Yang, X., Yu, X., Wang, J., Xiao, C., An, N. A., Han, C., Li, C., & Ding, W. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae503 · Cited by 6
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.